All News
Smartwatches to measures axSpA activity?
Upadacitinib use in axSpA INCREASED physical activity based on a wearable medical device step count, especially in those who were originally sedentary.
@RheumNow #ACR23 Abs#0530
#ACRbest https://t.co/oOFiQwMFZ6
Robert B Chao, MD ( View Tweet)
SLE pts with +aCL IgG/IgM and LA had higher risk of developing atherosclerotic CVD accdg to this prospective study by Ding et al.
. . .
🧐Again, SLE pts have ⬆️CV risk so always risk stratify and intervene early.
#ACR23 ABST0552 @RheumNow https://t.co/QhttQZzp8G
sheila ( View Tweet)
Year in Review by Dr. P Seo
NORD-STAR trial:
⭐️Abatacept or Certolizumab >> Tociluzumab > triple therapy in tx of 812 early RA patients based on clinical & radiographic results
➡️tx-naive, all got MTX
➡️mod-sev dz activity
➡️randomized to 48 wks therapy
#ACR23 @RheumNow https://t.co/vy2uYuyOse
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Interesting question... but feels like some time related bias or perhaps confounding?
Seems implausible that MTX & biologic would be protective for PsO & harmful for PsA
@RheumNow #ACR23 Abstr 0498 https://t.co/pSRoLHRTAm
Mike Putman EBRheum ( View Tweet)
NAFLD a real issue in RA
Does DMARD choice matter?
National Taiwanese data
newly dx RA n=41791
HCQ reduced NAFLD risk: adjHR 0.75
(other RF: obesity, NSAIDs, even low-dose PNL; but not DM, MTX)
Can HCQ improve liver health in RA?
Authors: ?adiponectin
#ACR23 ABST0396 @RheumNow https://t.co/9VMJpImFKs
David Liew drdavidliew ( View Tweet)
C-VIEW study on certolizumab use in preventing anterior uveitis in high risk pts with axSpA.
All pts were B27+ w/ at least one episode of anterior uveitis
Uveitis flares lower in certolizumab group compared to non-bDMARD use
@RheumNow #ACR23 Abs#0524 https://t.co/CfnhzStBMv
Robert B Chao, MD ( View Tweet)
This study by Munoz-Grajales et al show that the analyte S100A8/A9 (highest AUC) was able to differentiate between SLE pts with cognitive impairment and those without.
. . .
Interesting findings.
More data needed to confirm and explain why it is so.
#ACR23 ABST0558 @RheumNow https://t.co/LcF6s2qgNr
sheila ( View Tweet)
PROs are useful for tracking RA disease activity over time outside of the clinic setting for patients initiating new treatments without clinician-derived measures. Correlations in follow-up CDAI and PROs were 0.38 – 0.56, Nowell Abst#0380 #ACR23 @RheumNow https://t.co/LepCZ7sPY8 https://t.co/UYcZzIFEsx
Dr. Antoni Chan ( View Tweet)
#CV risk in #AxSpA in Korean population study N=71001, age 42, 71%M but 16% #MTX, 58% #SSZ. #TNFi vs none 30% less CVE. IL17 NO CV reduction but ?confounded by line of #Rx and v large N for TNFi. Study stated PRIOR to IL17i approval #ACR23 @ACRheum @RheumNow L11 poster ?Rx bias https://t.co/3Sft5KUlLa
Janet Pope ( View Tweet)
Nice VA study evaluating risk of lung cancer w/respect to RA treatment strategies
Take home? No association. Aside from the (small risk) w/JAKi's, I think malignancy risks have been mostly overblown
@NamrataRheum @RheumNow ABST0453 #ACR23 https://t.co/lDz0nV1KHt
Mike Putman EBRheum ( View Tweet)
Low-grade troponin rises in RA: ignore, or meaningful?
@BrighamWomens RA pts n=329
baseline hs-cTnT
Trops actually predict MACE:
HR 6.62
independent of traditional CV risk, CRP
Traditional CV RF not enough in RA
Maybe smoke does predict future fire?
#ACR23 ABST0387 @RheumNow https://t.co/33ZCgzYIl4
David Liew drdavidliew ( View Tweet)
Let’s talk about SEX! >30% of pts wished their rheums asked them about sexual health, >50% pts with sexual dysfunction have RA. The presence of menopause, younger age, and children were assc with sexual dysfunction. presenter Dr D Flores Abstr#0145, #abst#0146 #ACR23 @RheumNow https://t.co/9AdoTtEwFp
TheDaoIndex KDAO2011 ( View Tweet)
Patient reported outcomes between clinic visits: worth doing?
RA pts starting ADA/UPA, n=150
ArthritisPower/PatientSpot app for PROs between visits
52% of CDAI change explained by PROs
Maybe a helpful tool in prioritising RA clinic reviews?
@RADoctor #ACR23 ABST0380 @RheumNow https://t.co/oTttAlIxQR
David Liew drdavidliew ( View Tweet)
RheumNow’s expanded coverage of the #ACR23 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty
Dr. John Cush RheumNow ( View Tweet)
You should not tire of hearing this! Phase2 RCT of #dazodalibep -CD40L antagonist for #extra glandular & could also have #glandular problems in #Sjogrens was + improving Facit #fatigue & ESSPRI, etc. #GameChanger #ACR23 #ACRbest @ACRheum @RheumNow Pos#L10 https://t.co/DfChrAyslL
Janet Pope ( View Tweet)
PEXIVAS results: the reduced-dose GC regimen associated w/ ^ death, ESRD, and uncontrolled dz risk in severe GPA/MPA pts. Even greater risk in pts w/ creatinine levels > 300 μmol/L & in those tx w/ RTX induction. #ACR23 Plenary 0725 https://t.co/mBMrEaGj5k @rheumnow https://t.co/flAfYEKSXJ
Dr. Rachel Tate ( View Tweet)
DESIR cohort update in Abs #0513 shows axSpA pt imaging doesn't "worsen" after pregnancy. However, following 1st pregnancy, can see slight increase in L SIJ score, but typically not enough to define "worsening." #ACR23 https://t.co/HaYj3RQGFb @rheumnow https://t.co/5MQCXS1Kat
Dr. Rachel Tate ( View Tweet)
Acute pregnancy-related CV event risk found to be highest in pts w/ SLE+ APS, followed by primary APS, and SLE w/ LN. Most importantly, 25-30% of events happen post-partum! Monitor these pts carefully! #ACR23 Plenary 0722 #ACRbest https://t.co/yD5VFJ2SXh @rheumnow https://t.co/PDvzbs19fR
Dr. Rachel Tate ( View Tweet)
Prof Mustelin explains why Basic Science research is important in medicine. New ideas need:
👉discovery
👉explanation
👉 impact
#ACR23 @rheumnow #YearInReview #BasicScience https://t.co/t0W3GdUtWD
TheDaoIndex KDAO2011 ( View Tweet)
Who knew? VEXAS =cluster of findings from a somatic mutation N=110 studying retention of advanced Rx. #JAKi had far better retention than other #Rx. Although there could be channeling bias, I am impressed! Access for off label is a different issue #L03 #ACR23 @RheumNow @ACRheum https://t.co/RE4BVdZeWt
Janet Pope ( View Tweet)